Sagimet Biosciences Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-158.3M | $56.7M |
| FY2022 | — | $-187.0M | $158.0K |
| FY2023 | — | $91.1M | $75.1M |
| FY2024 | — | $155.8M | $75.8M |
| FY2025 | — | $111.4M | $35.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-158.3M | $56.7M |
| FY2022 | — | $-187.0M | $158.0K |
| FY2023 | — | $91.1M | $75.1M |
| FY2024 | — | $155.8M | $75.8M |
| FY2025 | — | $111.4M | $35.0M |